Philadelphia Business Journal | John George | February 1, 2013
InfraScan, a Philadelphia medical-device company, has received Food and Drug Administration approval for its new and improved Infrascanner Model 2000.
What it is: The Infrascanner Model 2000 is a noninvasive handheld brain hematoma detector. It is used to detect intracranial bleeding, identifying those patients who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
Who helped: The device was developed in a partnership with the U.S. Navy and Marine Corps.
Improvements: The new model — described by a company as a “ruggedized, integrated, user-friendly unit” — features upgrades that meet the specifications of the Marines. Its features include a disposable patient interface that uses near-infrared technology to identify bleeding inside the skull.
About traumatic brain injury: Each year, an estimated 1.5 million people in the United States, and 10 million people worldwide, seek medical treatment for head trauma. Intracranial hematomas resulting from a traumatic brain injury are life-threatening and have been reported to occur as the primary injury in 40 percent of patients with severe head injury. The rate of successful treatment improves with the timely diagnosis and intervention.
What the CEO is saying: “FDA approval in the U.S. allows InfraScan to offer an industry first — a powerful tool for use by civilian and military medical professionals to quickly triage head trauma patients,” said Baruch Ben Dor, InfraScan’s president and CEO. “Shortening the time to treatment through effective detection of intracranial bleeding can mean preserving brain function in a patient and even saving lives.”
You can read more about how InfraScan got its start here.